Characterization of MYC protein expression by western blot in tumors from the previously described in vivo treatment experiments with the DKO LnCap/AR and 22PC prostate models of transformation (Fig. 3a), as well as with the MSK_Lx151 lung combined NSCLC/SCLC model (Fig. 3f, g), revealed strong upregulation of MYC expression by targeted therapy in all 3 models, which was suppressed in the combo-treated tumors (Fig. 5a). The gene discussed is MYC; the disease is non-small cell lung carcinoma.